Side-by-side comparison
| Attribute | Compounded tirzepatide | Mounjaro® (brand) |
|---|---|---|
| FDA-approved indication | None (not FDA-approved) | Type 2 diabetes |
| Manufacturer | 503A or 503B pharmacy | Eli Lilly |
| Monthly cash price (full) | $186–$379/mo | ~$1,069/mo (cash MSRP) |
| Insurance coverage | No (cash-pay only) | Broad for T2D; PA often required |
| Medicare Part D | No | Yes (for T2D) |
| Form factor | Multi-dose vial | Pre-filled single-dose pen |
| Quality assurance | USP <71> / USP <85> / HPLC CoA (provider-dependent) | FDA-inspected cGMP |
Mounjaro vs Zepbound — same molecule, different labels
Mounjaro and Zepbound are both tirzepatide manufactured by Eli Lilly. The FDA approved Mounjaro for type 2 diabetes first (May 2022); Zepbound was approved for chronic weight management later (November 2023) and for obstructive sleep apnea (December 2024). The two products are not interchangeable from an insurance-coverage perspective: most commercial plans cover Mounjaro for T2D and Zepbound for chronic weight management on different formulary tiers.
When does compounded tirzepatide make sense in T2D?
Brand Mounjaro is usually the cost-effective path for type 2 diabetes patients with commercial insurance because the FDA indication is direct and formulary coverage is broad. Compounded tirzepatide is most commonly used off-label for chronic weight management when patients lack coverage for brand Zepbound. For T2D specifically, patients should typically pursue Mounjaro coverage first.